Cantor Fitzgerald Comments on XENE FY2025 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Xenon Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the biopharmaceutical company will post earnings per share of ($2.41) for the year. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share.

Several other research analysts have also commented on XENE. HC Wainwright reiterated a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Raymond James reissued an “outperform” rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $56.00.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $39.98 on Thursday. Xenon Pharmaceuticals has a one year low of $35.53 and a one year high of $50.99. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -14.18 and a beta of 1.20. The firm has a 50-day simple moving average of $40.23 and a two-hundred day simple moving average of $40.79.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same period in the previous year, the firm earned ($0.73) EPS.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Blue Trust Inc. increased its stake in shares of Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares during the period. Avior Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals in the fourth quarter valued at $101,000. nVerses Capital LLC acquired a new stake in Xenon Pharmaceuticals during the 3rd quarter worth about $102,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 487 shares during the last quarter. Finally, KBC Group NV lifted its holdings in shares of Xenon Pharmaceuticals by 39.8% in the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 780 shares during the period. 95.45% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the transaction, the director now directly owns 23,573 shares in the company, valued at $968,378.84. This trade represents a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.